Cetuximab and panitumumab in @entity984 wild-type XXXX : a meta-analysis.

@entity1 @entity470 @entity984 @entity5 @entity14
BACKGROUND: Anti- @entity470 monoclonal antibodies (panitumumab [P] and cetuximab [C]) are approved and effective only in @entity984 wild-type @entity1 with advanced @entity14 . The purpose of our meta-analysis is to evaluate the real effects of C and P in @entity984 wild-type @entity1 treated in randomized trials. @entity1 AND METHODS: Eligible studies included prospective, randomized, and controlled trials in which either C or P had been added to standard antineoplastic therapy or best supportive care and data for @entity984 wild-type @entity1 only had been calculated. Six thousand three hundred ninety-five @entity1 ' @entity5 samples have been analyzed (total wild-type n = 3,254; experimental arm n = 1,608; control arm n = 1,646). Relative risks (RRs) with 95% confidence intervals (CIs) for response rate were calculated, as well as hazard ratios (HRs)for progression-free survival (PFS) and overall survival. RESULTS: The overall RR of response rate is 1.69 (p = 0.003) in all trials. The overall HRs for PFS and survival are 0.65 (p = 0.0006) and 0.84 (p = 0.03), respectively, and both are significant. The HRs for PFS and survival in C trials are 0.64 and 0.79, respectively, and 0.65 and 0.87, respectively, in P trials, although only the results achieved in P trials are significant (p = 0.0007 and p = 0.03). Both response rate (RR = 10.94) and PFS (HR = 0.51) have increased more in pretreated @entity1 than in first-line trials. CONCLUSION: The addition of anti- @entity470 monoclonal antibodies to standard anticancer therapy in @entity984 wild-type @entity14 showed an overall significantly increased risk of objective response rate and increased progression-free and overall survival. Only the results achieved in P randomized trials are significant, and the strongest results have been achieved in pretreated @entity1 .
